Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936500 | 0.91 | FFAR4 (0.57) | FFAR4PPARAHRH3 | |
| SCHEMBL2885997 | 0.87 | FFAR4 (0.42) | FFAR4NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6696278 | 0.80 | FFAR4 (0.43) | FFAR4NPC1RAB9APTPN7PPARG | |
| SCHEMBL4938902 | 0.80 | FFAR4 (0.51) | FFAR4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4928507 | 0.78 | FFAR4 (0.55) | FFAR4ALDH1A1MAPTSMN1; SMN2MAOB | |
| SCHEMBL6430135 | 0.75 | FFAR4 (0.53) | FFAR4PPARAMAOBHRH3 | |
| SCHEMBL4651759 | 0.74 | FFAR4 (0.56) | FFAR4MAOBHRH3 | |
| SCHEMBL2985236 | 0.74 | HTR2A (0.58) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4650715 | 0.74 | FFAR4 (0.60) | FFAR4RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17028645 | 0.73 | FFAR4 (0.82) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6939990-B2 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | SDHA, GOT2, MDH2 | FFAR4 806/4885NPC1 835/4885RAB9A 3411/4885 |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | DDC, DAO, AADAT | FFAR4 816/4885NPC1 4149/4885RAB9A 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.